Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kamel Izeradjene"'
Autor:
Hattie Xu, Sean Durning, Noah Pefaur, Yoshiko Akamatsu, Andrew Urick, Fiona A. Harding, Jennifer D. Stone, Kamel Izeradjene, Adam S. Chervin, John Harlan, Ningyan Wang, Enrico L. Digiammarino, Travis Durkin
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38f29d20d1c6bffeaba8e43e31182748
https://doi.org/10.1096/fasebj.2020.34.s1.03302
https://doi.org/10.1096/fasebj.2020.34.s1.03302
Autor:
Melissa Best, William M. Grady, David A. Tuveson, Chelsea Combs, Ralph H. Hruban, Aarthi Gopinathan, Amary Wagner, Chu-Xia Deng, N. Volkan Adsay, Sunil R. Hingorani, Kamel Izeradjene
Publikováno v:
Cancer Cell. 11(3):229-243
SummaryOncogenic Kras initiates pancreatic tumorigenesis, while subsequent genetic events shape the resultant disease. We show here that concomitant expression of KrasG12D and haploinsufficiency of the Smad4/Dpc4 tumor suppressor gene engenders a dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4372b9a2ed4a859aaaae49f9c8d7c3c
Autor:
Kamel Izeradjene, Mike Tillman, Katalin Nagy, Janet A. Houghton, Carlotta Spano, László Kopper, Pierfranco Conte, Rudolf Mihalik, Helga Barti-Juhasz, Massimo Dominici, Kinga Székely-Szüts, Gian Luca Cervo, István Peták, Leslie Douglas
Publikováno v:
Pathology & Oncology Research. 12:133-142
The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0bfb9e2697c17844840bf772d6140a
https://doi.org/10.1007/bf02893359
https://doi.org/10.1007/bf02893359
Publikováno v:
Cancer Research. 65:7436-7445
The effects of reactive oxygen species (ROS) on tumor necrosis factor–related apoptosis–inducing ligand (TRAIL)–induced apoptosis in solid cancers have yet to be clearly defined. In this study, we found that the classic uncoupler of oxidative p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8400fdb73c4e7e20373401a9103af4
https://doi.org/10.1158/0008-5472.can-04-2628
https://doi.org/10.1158/0008-5472.can-04-2628
Publikováno v:
Oncogene. 24:2050-2058
Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli, as well as being elevated in many human cancers examined. We have demonstrated that CK2 is a key survival factor that protects human colon carcinoma cells from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f462e0838a14419a81b804e959d06ea
https://doi.org/10.1038/sj.onc.1208397
https://doi.org/10.1038/sj.onc.1208397
Publikováno v:
Clinical Cancer Research. 10:6650-6660
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis via the death receptors DR4 and DR5 in transformed cells in vitro and exhibits potent antitumor activity in vivo with minor side effects. Protein kinase casein kinase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd0552e5b7fca2ab0981f956e84e4b9
https://doi.org/10.1158/1078-0432.ccr-04-0576
https://doi.org/10.1158/1078-0432.ccr-04-0576
A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells
Autor:
M. Anozie, Kinga Szekely Szucs, Darren C. Phillips, David M. Tillman, Leslie Douglas, István Peták, Janet A. Houghton, Reka Vernes, Kamel Izeradjene
Publikováno v:
Cell Death & Differentiation. 10:729-739
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) belongs to the Tumor necrosis factor (TNF) family of death-inducing ligands, and signaling downstream of TRAIL ligation to its receptor(s) remains to be fully elucidated. Components of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aead2c0170923411916260d52202bd6c
https://doi.org/10.1038/sj.cdd.4401232
https://doi.org/10.1038/sj.cdd.4401232
Autor:
Kathleen E. DelGiorno, Libing Feng, Sunil R. Hingorani, Philamer Calses, Martin C. Whittle, Ralph H. Hruban, P. Geetha Rani, Laura D. Wood, Shelley M. Thorsen, Amy Chang, Kamel Izeradjene, Michael Goggins, Markus A. Carlson
Publikováno v:
Cell. 161(6)
Summary For the majority of patients with pancreas cancer, the high metastatic proclivity is life limiting. Some patients, however, present with and succumb to locally destructive disease. A molecular understanding of these distinct disease manifesta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595004c6146e75ea56dedc33cf98228e
https://pubmed.ncbi.nlm.nih.gov/26046433
https://pubmed.ncbi.nlm.nih.gov/26046433
Autor:
J. Scott Brockenbrough, Markus A. Carlson, Sunil R. Hingorani, Carlos Cuevas, Randi M Simmons, Philip D. Greenberg, Kamel Izeradjene, Ingunn M. Stromnes
Background Pancreatic ductal adenocarcinoma (PDA) is characterised by a robust desmoplasia, including the notable accumulation of immunosuppressive cells that shield neoplastic cells from immune detection. Immune evasion may be further enhanced if th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0c89fded41c5680ff2b718f435ef3b
https://europepmc.org/articles/PMC4340484/
https://europepmc.org/articles/PMC4340484/
Publikováno v:
International Immunology. 13:85-93
Methotrexate (MTX), a folate antagonist with multiple enzymatic targets, is used in the treatment of malignancies as well as in autoimmune and chronic inflammatory diseases, and ZD1694 (tomudex), a water-soluble quinazoline specific inhibitor of thym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f35635a062a43e8b6da2166fad3d395
https://doi.org/10.1093/intimm/13.1.85
https://doi.org/10.1093/intimm/13.1.85